Novartis AG Stock News

Novartis (NVS) faces a setback in the patent litigation with respect to the blockbuster heart disease drug Entresto. Shares decline.

The pharmaceutical giant suffered a setback with one of its top-selling drugs. The patent for Entresto was invalidated in a court proceeding.

Novartis (NVS) signs a deal to divest Xiidra and SAF312 (libvatrep) to Bausch + Lomb for $2.5 billion.

Eye care company Bausch + Lomb said it would pay $1.75 billion to acquire a portfolio of eye care products from Swiss healthcare giant Novartis.

Bausch + Lomb Corp has announced plans to buy dry eye disease treatment Xiidra from Swiss pharma giant Novartis AG (ADR) (NYSE:NVS) in a deal that could be valued as high as $2.5 billion. The two comp

Bausch + Lomb Corp. BLCO, +7.98% confirmed that it was buying the “dry eye” treatment Xiidra from Novartis AG NVS, +0.90% NOVN, +0.72% in a deal valued at $2.5 billion. Under terms of the deal, Ba

Bausch + Lomb Corp. BLCO, +7.98% confirmed that it was buying the “dry eye” treatment Xiidra from Novartis AG NVS, +0.90% NOVN, +0.72% in a deal valued at $2.5 billion. Under terms of the deal, Ba

Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Novartis (NVS) or Eli Lilly (LLY). But which of these two stocks is more attractive to value investor

Toll Brothers (TOL), Walmart (WMT), Caterpillar (CAT), W.W. Grainger (GWW) and Novartis (NVS) could be compelling picks heading into the second half of the year.

Juha Anjala, co-head of EMEA health-care investment banking at JPMorgan, discusses government support for investment in life sciences, as well as innovation in the sector.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Cosentyx is highly effective for a skin condition known as hidradenitis suppurativa. The new indication could have blockbuster potential for Novartis.

That value proposition took a huge step forward on Monday when Novartis announced a $3.2 billion acquisition of Seattle-based biotechnology company Chinook Therapeutics. A specialist in the developmen

Chinook Therapeutics (NASDAQ: KDNY ) has been surging all day. Why? KDNY stock surged on news that multinational pharmaceutical giant Novartis (NYSE: NVS ) will acquire the firm, which is known for ki